Pfizer has COVID-19 vaccine ready in October 2020? Albert Bourla explains


The race towards a new coronavirus (COVID-19) vaccine has yet to end. Headquartered in New York City, New York, United States, Pfizer is one of the pharmaceutical companies joining the race.

Pfizer Pharmaceuticals chief executive officer Albert Bourla recently gave an update. In an interview with the NBC news program “TODAY” on September 8, 2020, he said the New York City-based pharmaceutical company “will have an answer” by the end of October 2020.

This does not mean, however, that Pfizer will start an actual distribution of a COVID-19 vaccine in October 2020, Bourla clarified. According to him, the company  will submit a vaccine to the Food and Drug Administration for authorization only when it obtains data showing “evidence of safety and efficacy.”


But finding a safe and effective vaccine does not solve all the problems related to the COVID-19 pandemic. Apparently, not everyone is interested in getting vaccinated.

Out of the 1,000 respondents of a poll conducted by NPR, PBS NewsHour and Marist from August 3-11, 2020, only 60 percent said they would receive a COVID-19 vaccine. On the other hand, 35 percent said they would not while 5 percent are uncertain.

Two-thirds of U.S. voters said they would not try to get a COVID-19 vaccine as soon as it becomes available, according to a poll by USA TODAY and Suffolk. Also, 25 percent of the respondents said they do not want to ever get it.

Once COVID-19 vaccine is available, those who decide against taking it will not only affect their lives, according to Bourla. The Pfizer Pharmaceuticals CEO explained that these people will affect the lives of others because they will become “the weak link” that will allow the virus to replicate if they do not vaccinate.

Also on September 8, 2020, Pfizer, GlaxoSmithKline, AstraZeneca and six other vaccine developers from the U.S. and Europe made a “historic pledge.” The companies vowed to “uphold the integrity of the scientific process as they work towards potential global regulatory filings and approvals of the first COVID-19 vaccines,” CNBC quoted them as saying in a joint statement.

1 reply »

Leave a Reply

Fill in your details below or click an icon to log in: Logo

You are commenting using your account. Log Out /  Change )

Google photo

You are commenting using your Google account. Log Out /  Change )

Twitter picture

You are commenting using your Twitter account. Log Out /  Change )

Facebook photo

You are commenting using your Facebook account. Log Out /  Change )

Connecting to %s

This site uses Akismet to reduce spam. Learn how your comment data is processed.